Interestingly, an E2F4 activation expression signature associated with sensitivity to palbociclib and resistance to aromatase inhibitors (Guerrero‐Zotano et al., 2018) was higher in IBC than in non‐IBC samples, notably in HR+/HER2− patients. The gene discussed is CYP19A1; the disease is inflammatory breast carcinoma.